107932-97-8

Basic information

• Product Name: 2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile
• Synonyms: 2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile;2-cyanomethylimidazo(4,5-b)pyridine;2-(3H-IMidazo[4,5-b]pyridin-2-yl)acetonitrile
• CAS NO: 107932-97-8
• Molecular Formula: C₈H₆N₄
• Molecular Weight: 158.16
• Mol File: 107932-97-8.mol

Chemical Properties

• Melting Point: 268-270 °C(Solv: N,N-dimethylformamide (68-12-2); water (7732-18-5))
• Boiling Point: 468.1°Cat760mmHg
• Flash Point: 148.8°C
• Appearance: /
• Density: 1.381g/cm³
• Vapor Pressure: 6.19E-09mmHg at 25°C
• Refractive Index: 1.698
• PKA: 6.11±0.20(Predicted)
• CAS DataBase Reference: 2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile(107932-97-8)
• EPA Substance Registry System: 2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile(107932-97-8)

Safety Data

• Hazardous Substances Data: 107932-97-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile is used as a building block in organic synthesis for the creation of novel compounds with potential applications in various industries. Its unique structure allows for the formation of new chemical bonds and the synthesis of complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile is used as a precursor in the development of new drugs. Its unusual structure may provide a basis for the design of innovative pharmaceutical compounds with unique therapeutic properties.
Used in Material Science:
2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile is also used in material science for the development of new materials with specific properties. Its potential reactivity and unique structure may contribute to the creation of advanced materials for various applications.
However, it is important to note that further research and analysis are required to fully understand the properties and potential uses of 2-(2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-8-yl)acetonitrile in these fields.

InChI:InChI=1/C8H6N4/c9-4-3-7-11-6-2-1-5-10-8(6)12-7/h1-2,5H,3H2,(H,10,11,12)

Upstream product

• 452-58-4 2,3-Diaminopyridine 
• 105-56-6 ethyl 2-cyanoacetate 
• 107-91-5 cyanoacetic acid amide 

Downstream Products

• 137242-47-8 (E)-3-(2,4-Dimethyl-phenyl)-2-(3H-imidazo[4,5-b]pyridin-2-yl)-acrylonitrile 
• 137242-50-3 (Z)-3-(2,4-Dimethyl-phenyl)-2-(3H-imidazo[4,5-b]pyridin-2-yl)-thioacrylamide 

Relevant articles and documents

Lithium bromide catalyzed solvent free method for synthesis of 2-substituted benzimidazoles and imidazopyridines

The first successful lithium bromide mediated solvent free condensation of arylenediamine and esters to obtain 2-substituted benzimidazole and imidazopyridine in good to excellent yields is described.

Novel imidazo[4,5-b]pyridine derived acrylonitriles: A combined experimental and computational study of their antioxidative potential

We describe the synthesis of novel unsubstituted and N-substituted imidazo[4,5-b]pyridine derived acrylonitriles, which were prepared by classical and microwave assisted organic synthesis. Their antioxidative potential was studied using spectroscopic DPPH

Synthesis and DFT studies of novel aminoimidazodipyridines using 2-(3H-imidazo[4,5-b]pyrid-2-yl)acetonitrile as an efficient key precursor

Novel 9-aminoimidazo[1,2-a:5,4-b']dipyridine-6,8-dicarbonitriles were prepared via the Michael addition reaction of readily accessible 2-(3H-imidazo[4,5-b]pyrid-2-yl)acetonitrile with arylidenemalononitriles. The regioselectivity of the reaction was supported by theoretical calculations at the DFT level. In contrast, the reaction of the appropriate bis-arylidenemalononitrile with 2-(3H-imidazo[4,5-b]pyrid-2-yl)acetonitrile under similar reaction conditions gave the corresponding bis[2-(3H-imidazo[4,5-b]pyrid-2-yl)acrylonitriles].

Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model

Further structure-activity relationship (SAR) studies on the recently identified pyrido[1,2-a]benzimidazole (PBI) antimalarials have led to the identification of potent, metabolically stable compounds with improved in vivo oral efficacy in the P. berghei mouse model and additional activity against parasite liver and gametocyte stages, making them potential candidates for preclinical development. Inhibition of hemozoin formation possibly contributes to the mechanism of action.

Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein

Human APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, A3G) is a potent restriction factor against human immunodeficiency virus type 1 (HIV-1) by inducing hypermutation of G to A in viral genome after its incorporation into virions. HIV-1 Vif (Virion Infectivity Factor) counteracts A3G by inducing ubiquitination and proteasomal degradation of A3G protein. Vif-A3G axis therefore is a promising therapeutic target of HIV-1. Here we report the screening, synthesis and SAR studies of benzimidazole derivatives as potent inhibitors against HIV-1 replication via protecting A3G protein. Based on the steep SAR of the benzimidazole scaffold, we identified compound 14 and 26 which provided the best potency, with IC50 values of 3.45 nM and 58.03 nM respectively in the anti-HIV-1 replication assay in H9 cells. Compound 14 and 26 also afforded protective effects on A3G protein level. Both compounds have been proved to be safe in acute toxicological studies. Taken together, we suggest that these two benzimidazole derivatives can be further developed as a new category of anti-HIV-1 leads.

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

Inhibition of FGFR3 and treatment of multiple myeloma

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

IMIDAZO(1,2-a)PYRIDINE DERIVATIVE

A compound reprsented by the following formula (I), its salts or nsolvates thereof capable of specifically or selectively expressig an antifungal activity in a broad spectrum based on the novel mechanism thereof of 1,6-β-glucan synthesis inhibition, and an antifungal agent containing any of them.

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Quinolinone derivatives

Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.